Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lundsgaard-Hansen

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Vox Sanguinis|January 1, 1976
Can a national all voluntary blood transfusion service by adequate blood component therapy cover actual and future needs of albumin?L F Barker, P Cazal, H G Haussman, et al.
The Journal of Surgical Research|December 1, 1972
Circulatory deterioration as the determinant of energy metabolism in endotoxin shockP Lundsgaard-Hansen, E Pappova, B Urbaschek, et al.
Die Infusionstherapie|December 1, 1974
[Clinical plasma substitution with gelatin: A 12-year experience with 39,320 units of Physiogel]B Tschirren, U Affolter, R Elsässer, et al.
Vox Sanguinis|January 1, 1978
Red cells and gelatin as the core of a unified program for the national procurement of blood components and derivatives. Prediction, performance, and impact on supply of albumin and factor VIIIP Lundsgaard-Hansen, U Bucher, B Tschirren, et al.
Vox Sanguinis|January 1, 1979
To which extent is the clinical use of dextran, gelatin and hydroxyethyl starch influenced by the incidence and severity of anaphylactoid reactions?J A Collins, M S Litwin, H Lutz, et al.
Vox Sanguinis|January 1, 1977
Acute hypoproteinemic fluid overload: its determinants, distribution, and treatment with concentrated albumin and diureticsE Pappova, W Bachmeier, J L Crevoisier, et al.
Bulletin of the World Health Organization|January 1, 1983
Use of plasma volume substitutes and plasma in developing countriesP Lundsgaard-Hansen, J A Collins, A S David-West, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Vox Sanguinis|January 1, 1976
Can a national all voluntary blood transfusion service by adequate blood component therapy cover actual and future needs of albumin?L F Barker, P Cazal, H G Haussman, et al.
The Journal of Surgical Research|December 1, 1972
Circulatory deterioration as the determinant of energy metabolism in endotoxin shockP Lundsgaard-Hansen, E Pappova, B Urbaschek, et al.
Die Infusionstherapie|December 1, 1974
[Clinical plasma substitution with gelatin: A 12-year experience with 39,320 units of Physiogel]B Tschirren, U Affolter, R Elsässer, et al.
Vox Sanguinis|January 1, 1978
Red cells and gelatin as the core of a unified program for the national procurement of blood components and derivatives. Prediction, performance, and impact on supply of albumin and factor VIIIP Lundsgaard-Hansen, U Bucher, B Tschirren, et al.
Vox Sanguinis|January 1, 1979
To which extent is the clinical use of dextran, gelatin and hydroxyethyl starch influenced by the incidence and severity of anaphylactoid reactions?J A Collins, M S Litwin, H Lutz, et al.
Vox Sanguinis|January 1, 1977
Acute hypoproteinemic fluid overload: its determinants, distribution, and treatment with concentrated albumin and diureticsE Pappova, W Bachmeier, J L Crevoisier, et al.
Bulletin of the World Health Organization|January 1, 1983
Use of plasma volume substitutes and plasma in developing countriesP Lundsgaard-Hansen, J A Collins, A S David-West, et al.
Pageof 7